Recida Therapeutics

Focused on developing first-in-class anti-infective medicines for the treatment of multi-drug resistant infections

Recida is a Frazier-founded company focused on developing first-in-class anti-infective medicines for the treatment of multi-drug resistant infections. The company is currently advancing its novel LpxC inhibitor, RC-01, into Phase 1 clinical trials. Recida is led by an experienced team of pharmaceutical and anti-infectives executives seeking to improve outcomes for patients with multi-drug resistant and other difficult-to-treat infections.

Year of Investment

2016

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

Menlo Park, California